Literature DB >> 19054170

Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association.

Shiro Hinotsu1, Hideyuki Akaza, Tsuneharu Miki, Hiroyuki Fujimoto, Nobuo Shinohara, Eiji Kikuchi, Yoichi Mizutani, Hirofumi Koga, Eijiro Okajima, Akihiko Okuyama.   

Abstract

OBJECTIVES: It is generally recognized that cigarette smoking is the most important risk factor for bladder cancer. The present study was undertaken to examine the relationships between smoking history of bladder cancer patients and the age of onset of bladder cancer and tumor characteristics.
METHODS: The present study examined the data for 5959 cases (4728 males and 1231 females) collected in the bladder cancer database of the Japanese Urological Association from 1999 to 2001. Patients were divided by smoking history into three categories as current non-smokers, current smokers and unknown smoking history. Relationship between smoking history and the age at diagnosis of bladder cancer, gender, T stage, grade, tumor size, tumor number and initial symptoms was analyzed.
RESULTS: In both males and females the onset of bladder cancer is about 6 years (6.1 years in males and 5.9 years in females) earlier for current smokers than for current non-smokers. At the time of diagnosis, tumor stage was significantly higher in the current smokers group. The current smokers group tended to have larger tumor size.
CONCLUSIONS: The finding of 6-year-earlier onset of bladder cancer among current smokers is of great importance to both health care and medical economics. It is essential to make people better informed concerning the need to quit smoking.

Entities:  

Mesh:

Year:  2008        PMID: 19054170     DOI: 10.1111/j.1442-2042.2008.02194.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  7 in total

1.  Cigarette smoking and subtypes of bladder cancer.

Authors:  Xuejuan Jiang; J Esteban Castelao; Jian-Min Yuan; Mariana C Stern; David V Conti; Victoria K Cortessis; Malcolm C Pike; Manuela Gago-Dominguez
Journal:  Int J Cancer       Date:  2011-05-09       Impact factor: 7.396

Review 2.  A glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers.

Authors:  Mohammed Merae Alshahrani
Journal:  Saudi J Biol Sci       Date:  2022-01-15       Impact factor: 4.052

3.  Bladder cancer in HIV-infected adults: an emerging concern?

Authors:  Sylvain Chawki; Guillaume Ploussard; Claire Montlahuc; Jérome Verine; Pierre Mongiat-Artus; François Desgrandchamps; Jean-Michel Molina
Journal:  J Int AIDS Soc       Date:  2014-11-02       Impact factor: 5.396

4.  Bladder cancer trends in Latvia during 1990-2017: incidence, mortality, and survival rates.

Authors:  Ērika Bitiņa-Barlote; Juris Plonis; Vinita Cauce; Egils Vjaters; Jānis Gardovskis; Edvīns Miklaševičs; Miki Nakazawa-Miklaševiča
Journal:  Cent European J Urol       Date:  2021-02-18

5.  Long non-coding RNA SNHG1 promotes bladder cancer progression by upregulating EZH2 and repressing KLF2 transcription.

Authors:  Jie Min; Jiaxing Ma; Qi Wang; Dexin Yu
Journal:  Clinics (Sao Paulo)       Date:  2022-09-07       Impact factor: 2.898

6.  Tolerability and Efficacy of Neoadjuvant Chemotherapy with a Tri-Weekly Interval Methotrexate, Doxorubicin, Vinblastine, and Cisplatin Regimen for Patients with Locally Advanced Bladder Cancer.

Authors:  Satoko Arai; Tomohiko Hara; Yoshiyuki Matsui; Keiichi Koido; Hironobu Hashimoto; Yasuo Shinoda; Motokiyo Komiyama; Hiroyuki Fujimoto; Hiroyuki Terakado
Journal:  Case Rep Oncol       Date:  2018-07-05

Review 7.  New Directions and Challenges in Targeted Therapies of Advanced Bladder Cancer: The Role of FGFR Inhibitors.

Authors:  Katarzyna Szklener; Paulina Chmiel; Adam Michalski; Sławomir Mańdziuk
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.